Trophos

Trophos
Privately held company
Fate Acquired by Hoffmann-La Roche
Founded Marseille, France (1999 (1999))
Founder
  • Christopher Henderson
  • Olivier Pourquie
  • Jean-Louis Kraus
  • Antoine Beret
  • Michel Delaage
Defunct 2015 (2015)
Website www.trophos.com

Trophos was a biopharmaceutical company specialising in the discovery and development of novel therapeutics to treat both orphan neurodegenerative diseases and more prevalent disorders.

Trophos was founded in 1999 in Marseille by three scientists, Christopher Henderson, Olivier Pourquie and Jean-Louis Kraus and two entrepreneurs, Antoine Beret and Michel Delaage. Trophos' lead compound was TRO19622 / olesoxime.[1][2] Olesoxime is a mitochondrial targeted compound, which is a member of a new class of therapeutic agents aimed at bringing significant therapeutic benefit to patients suffering from devastating neurological diseases.[3][4] Spinal Muscular Atrophy (SMA) is an autosomal recessive genetic disease that affects the motor neurons of the voluntary muscles used for activities such as crawling, walking, head and neck control and swallowing. SMA affects approximately 20,000 people worldwide. One in every 6,000 babies is born with SMA. It is the number one genetic cause of death in children under the age of two. Results from an international, double-blind, placebo-controlled phase II study involving 165 type II and non-ambulatory type III SMA patients, completed in February 2014 to assess safety and efficacy of olesoxime (TRO19622) were recently released. The data shows that patients treated with olesoxime were able to maintain motor function over the two-year period of the study and that typical health complications associated with SMA occurred less frequently than in patients treated with a placebo, leading to better well being.[5]

In January 2015, Hoffmann-La Roche announced its intention to buy Trophos for €120,000,000 upfront and up to €350,000,000 in milestone performance payments.[6][7]

References

  1. ↑ Bordet, Thierry; Buisson, Bruno; Michaud, Magali; Drouot, Cyrille; Galéa, Pascale; Delaage, Pierre; Akentieva, Natalia P.; Evers, Alex S.; Covey, Douglas F. (2007). "Identification and characterization of cholest-4-en-3-one, oxime (TRO19622), a novel drug candidate for Spinal Muscular Atrophy (SMA)". Journal of Pharmacology and Experimental Therapeutics. 322 (2): 709–20. doi:10.1124/jpet.107.123000. PMID 17496168.
  2. ↑ "olesoxime". UKMi New Drugs Online Database. Retrieved 2 January 2016.
  3. ↑ "Effect of TRO19622 in the Treatment of Patients With Chemotherapy Induced Peripheral Neuropathy". ClinicalTrialsFeeds.org. 5 February 2010. Retrieved 3 October 2010.
  4. ↑ "Safety and Efficacy of TRO19622 as add-on Therapy to Riluzole Versus Placebo in Treatment of Patients Suffering From Amyotrophic Lateral Sclerosis (ALS)". ClinicalTrialsFeeds.org. May 2010. Retrieved 3 October 2010.
  5. ↑ "Trophos will present results of pivotal phase II/III study of olesoxime in spinal muscular atrophy patients at the American Academy of Neurology (AAN)" (Press release). Trophos. 29 April 2014 – via AFM-Telethon.
  6. ↑ Franklin, Joshua (16 January 2015). "Roche buys France's Trophos to expand in neuromuscular disease". Reuters. Retrieved 30 December 2015.
  7. ↑ Staff (15 February 2015). "Roche to Buy Trophos for Up-to-$543M". Genetic Engineering & Biotechnology News (paper). 35 (4). p. 6.

Further reading

This article is issued from Wikipedia - version of the 5/8/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.